Sino Biopharmaceutical: Net profit in the first half of 2026 reached 104 million yuan, a year-on-year increase of 72.28%.

According to the announcement from BioShares, the operating income in the first half of 2026 reached 756 million yuan, an increase of 22.09% year-on-year. The net profit attributable to shareholders of the listed company was 104 million yuan, an increase of 72.28%, compared to a net profit of 60.424 million yuan for the same period last year. The net profit attributable to shareholders of the listed company, deducting non-recurring gains and losses, was 89.6856 million yuan, an increase of 178.61%.